GlassScriptPhysician profile
Jacquelyn Medina
NPI 1780143628
$8,055.52
in general payments reported to CMS, 2019-2025
29 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $69.62 · 2021: $581 · 2022: $1,318 · 2023: $2,541 · 2024: $1,519 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,531 · Travel and Lodging: $466 · Education: $90.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,531.12 |
| Travel and Lodging | $465.56 |
| Education | $90.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,438.90 | 2020-2025 | |
| Kerecis Limited | $1,275.02 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Regeneron Healthcare Solutions, INC. | $749.12 | 2022-2025 | Dupixent |
| Genzyme Corporation | $661.88 | 2021-2025 | |
| Ucb, INC. | $550.13 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $424.66 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $395.37 | 2023-2024 | Vtama |
| Lilly USA, LLC | $353.92 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $348.75 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $300.48 | 2021-2025 | Nemluvio |
| Incyte Corporation | $207.25 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $182.26 | 2021-2025 | |
| Lnhc, INC | $176.24 | 2025 | Zelsuvmi |
| Amgen INC. | $158.08 | 2023-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $145.84 | 2023 | Ycanth |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $144.13 | 2024-2025 | |
| Almirall LLC | $108.24 | 2023-2025 | Seysara |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Janssen Biotech, INC. | $75.10 | 2023-2024 | Tremfya |
| Organon LLC | $62.87 | 2025 | Vtama |
| Epi Health, LLC | $39.36 | 2020 | |
| Mayne Pharma Commercial LLC | $38.22 | 2023-2024 | |
| Pfizer INC. | $32.17 | 2025 | |
| Journey Medical Corporation | $23.45 | 2023 | |
| Biofrontera INC. | $20.82 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $18.28 | 2024 | |
| Revance Therapeutics, INC. | $16.68 | 2024 | Daxxify |
| Novo Nordisk INC | $14.38 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.